BioMarin Pharmaceutical Inc. (BMEA, Financial) has announced a new stock offering, which has been priced lower than its previous closing price of $2.90. Jefferies is taking the lead as the sole book-running manager for this offering, providing investors with an oversight on the financial maneuver.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Biomea Fusion Inc (BMEA, Financial) is $20.00 with a high estimate of $54.00 and a low estimate of $3.00. The average target implies an upside of 589.66% from the current price of $2.90. More detailed estimate data can be found on the Biomea Fusion Inc (BMEA) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Biomea Fusion Inc's (BMEA, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
